Two ASPS cases reported in J Pediatr Hematol Oncol in July 2016
Posted: Sat Jul 02, 2016 3:23 pm
In my view, there is nothing really new for us in these two case reports, but they might still be interesting. Below is the abstract, and attached the article.
Best,
Johannes
Treatment of Metastatic, Refractory Alveolar Soft Part Sarcoma: Case Reports and Literature Review of Treatment Options in the Era of Targeted Therapy.
J Pediatr Hematol Oncol. 2016 Jul;38(5):e169-72. doi: 10.1097/MPH.0000000000000571.
http://www.ncbi.nlm.nih.gov/pubmed/27164526
Kuo DJ1, Menell JS, Glade Bender JL.
BACKGROUND:
Alveolar soft part sarcoma is a rare soft tissue sarcoma that is characterized by a pattern of slow growth with metastases to the lung, bone, and brain that is not responsive to conventional cytotoxic chemotherapy.
OBSERVATIONS:
We describe 2 patients, with a combined 19 years of treatment experience including multiple different chemotherapeutic and targeted therapy regimens, surgery, and radiotherapy. We also present a review of the literature regarding treatment options to highlight recent findings.
CONCLUSIONS:
Alveolar soft part sarcoma is an indolent, but persistently progressive disease. Novel therapeutic agents hold promise in its management.
Best,
Johannes
Treatment of Metastatic, Refractory Alveolar Soft Part Sarcoma: Case Reports and Literature Review of Treatment Options in the Era of Targeted Therapy.
J Pediatr Hematol Oncol. 2016 Jul;38(5):e169-72. doi: 10.1097/MPH.0000000000000571.
http://www.ncbi.nlm.nih.gov/pubmed/27164526
Kuo DJ1, Menell JS, Glade Bender JL.
BACKGROUND:
Alveolar soft part sarcoma is a rare soft tissue sarcoma that is characterized by a pattern of slow growth with metastases to the lung, bone, and brain that is not responsive to conventional cytotoxic chemotherapy.
OBSERVATIONS:
We describe 2 patients, with a combined 19 years of treatment experience including multiple different chemotherapeutic and targeted therapy regimens, surgery, and radiotherapy. We also present a review of the literature regarding treatment options to highlight recent findings.
CONCLUSIONS:
Alveolar soft part sarcoma is an indolent, but persistently progressive disease. Novel therapeutic agents hold promise in its management.